mTOR Hyperactivation in down syndrome hippocampus appears early during development (Q48721008)

14 February 2018

title

mTOR Hyperactivation in down syndrome hippocampus appears early during development (English)

1 reference

14 February 2018

1 reference

6

1 reference

14 February 2018

Ivan Milenkovic

object named as

Ivan Milenkovic

3

0 references

Eleonora Aronica

7

object named as

Eleonora Aronica

1 reference

14 February 2018

Anand M Iyer

1

1 reference

14 February 2018

Jackelien van Scheppingen

2

1 reference

14 February 2018

Jasper J Anink

4

1 reference

14 February 2018

Homa Adle-Biassette

5

1 reference

14 February 2018

publication date

1 July 2014

1 reference

14 February 2018

Journal of Neuropathology & Experimental Neurology

published in

1 reference

14 February 2018

volume

73

1 reference

14 February 2018

issue

7

1 reference

14 February 2018

page(s)

671-683

1 reference

14 February 2018

Developmental neuroplasticity and the origin of neurodegenerative diseases

cites work

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Developmental mechanisms in the pathogenesis of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Neuro-archaeology: pre-symptomatic architecture and signature of neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

mTOR signaling in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Mammalian target of rapamycin (mTOR) pathways in neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

mTOR: A pathogenic signaling pathway in developmental brain malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Deregulated mTOR-mediated translation in intellectual disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Communication breaks-Down: from neurodevelopment defects to cognitive disabilities in Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Synaptic pathology of Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

The IL-1beta system in epilepsy-associated malformations of cortical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

The RSK family of kinases: emerging roles in cellular signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Differential distribution of group I metabotropic glutamate receptors in developing human cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Developmental distribution pattern of metabotropic glutamate receptor 5 in prenatal human hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Group I metabotropic glutamate receptors: a role in neurodevelopmental disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Group I metabotropic glutamate receptors activate the p70S6 kinase via both mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK 1/2) signaling pathways in rat striatal and hippocampal synaptoneurosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Dysregulation of mTOR signaling in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

The pathophysiology of fragile X (and what it teaches us about synapses)

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Correlation between clinical and histologic findings in the human neonatal hippocampus after perinatal asphyxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Stress and mTORture signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

The pathological association between Down syndrome and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Tuberous sclerosis complex and epilepsy: recent developments and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

The modular phosphorylation and activation of p70s6k.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

mTOR phosphorylated at S2448 binds to raptor and rictor

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

The mTOR pathway is activated in glial cells in mesial temporal sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Rapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Cell injury and premature neurodegeneration in focal malformations of cortical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Granulovacuolar degeneration (GVD) bodies of Alzheimer's disease (AD) resemble late-stage autophagic organelles

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

Neurofibrillary tangles, granulovacuolar degeneration, and neuron loss in Down Syndrome: quantitative comparison with Alzheimer dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FNEN.0000000000000083

10.1097/NEN.0000000000000083

21 January 2018

Identifiers

DOI

1 reference

14 February 2018

1 reference

14 February 2018